AlphaCore Capital LLC Purchases 18,313 Shares of Genmab A/S Sponsored ADR $GMAB

AlphaCore Capital LLC lifted its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 863.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,435 shares of the company’s stock after purchasing an additional 18,313 shares during the period. AlphaCore Capital LLC’s holdings in Genmab A/S were worth $627,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of GMAB. Orbis Allan Gray Ltd lifted its holdings in Genmab A/S by 38.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after buying an additional 2,209,659 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Genmab A/S by 152.3% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after acquiring an additional 2,084,966 shares in the last quarter. First Trust Advisors LP lifted its stake in Genmab A/S by 3.5% in the second quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock worth $36,575,000 after acquiring an additional 60,504 shares during the period. Brandywine Global Investment Management LLC lifted its stake in Genmab A/S by 1.6% in the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after acquiring an additional 27,372 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Genmab A/S by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after acquiring an additional 135,814 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on GMAB. Jefferies Financial Group began coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price for the company. HC Wainwright raised their price objective on shares of Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Wall Street Zen cut Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Finally, Morgan Stanley began coverage on Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.70.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $29.44 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The firm has a market cap of $18.91 billion, a price-to-earnings ratio of 18.99, a price-to-earnings-growth ratio of 1.20 and a beta of 0.90. The business has a 50-day simple moving average of $31.91 and a two-hundred day simple moving average of $30.18. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $35.43.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. On average, analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.